Earnings upgrades and price target lift for Paragon Care
This was assisted by the acquisitions of Designs for Vision, MediTron and Western Biomedical, initiatives that have not only provided additional revenue streams but have expanded the company’s geographic presence and product range.
Melbourne-based PGC is a leading provider of medical equipment, devices and consumables for the Australian and New Zealand healthcare market. Many of the products it offers have applications in treating conditions regularly found in the elderly, indicating that the company is leveraged to the ageing population thematic.
On this note the company distributes its products to aged care facilities, as well as the broader hospital and community care market.
In summing up fiscal 2016 John Hester from Bell Potter said, “PGC has transitioned from a subscale distributor into a vastly different proposition for investors seeking long-term earnings growth in the healthcare sector, without the regulatory risk typically associated with the sector via pricing, funding or compliance”.
However, it should be noted that analyst’s forecasts and price targets may not necessarily be met. Similarly, historical trading patterns should not be used as the basis for an investment decision as these may not be replicated in the future.
Importantly, strengthening of the business and a broadening of its distribution platform over the last two years has provided new avenues for management to explore in terms of continuing its growth by acquisition strategy.
PGC also has a healthy mix of products with good exposure to consumables that fall under the preventative services and maintenance areas, effectively providing income stability rather than relying on the sometimes unpredictable nature of the instrument and device distribution market.
Hester said he is expecting further acquisitions in fiscal 2017, noting that gearing was a very conservative 26%. He estimates the company has borrowing capacity up to approximately $40 million without the need to raise capital through an equity placement.
Taking into account the impressive fiscal 2016 result and the prospect of growth initiatives in the coming 12 months, Hester upgraded earnings per share forecasts for fiscal years 2017 and 2018 by 8.3% and 1.3% respectively.
He also upgraded the 12 month target price from 91 cents to 96 cents, implying a premium of circa 15% to Wednesday’s closing price of 82.7 cents.
This suggests there could be further upside in the group’s share price even after the significant spike that occurred in early August in response to the group’s results announcement.
PGC is trading on a fiscal 2017 PE multiple of 13 relative to Hester’s earnings forecasts. This appears conservative when compared with the high multiples usually attributed to companies in the healthcare sector. Furthermore, it doesn’t accurately reflect PGC’s growth prospects with Hester forecasting earnings per share accretion of 20% in fiscal 2017.
When the experts at Next Investors have a stock pick, it may pay to listen.
The Next Investors have been investing in ASX small cap stocks for years, with their best small cap picks yielding returns of 1,200%, 1,120%, 900% and 678%.
They have just revealed their hand-picked, FY2021 stock portfolio of high conviction long-term investments.
Click the link below to see what they are currently investing in.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.